AstraZeneca Plc reported better-than-expected third-quarter product sales on Thursday, on the back of strong demand for newer medicines including cancer treatments Tagrisso and Lynparza as well as growth in China.
Product sales for the three months ended Sept. 30 rose 18% to $6.13 billion on a constant-currency basis, the company's fifth consecutive quarter of growth after years of sliding sales due to patent losses on older medicines.
